BB
BB Biotech Portfolio holdings
AUM
$3.98B
This Quarter Return
+13.76%
1 Year Return
+15.06%
3 Year Return
+120.36%
5 Year Return
+263.74%
10 Year Return
–
AUM
$3.69B
AUM Growth
+$3.69B
(+9.9%)
Cap. Flow
+$61.5M
Cap. Flow
% of AUM
1.67%
Top 10 Holdings %
Top 10 Hldgs %
69.25%
Holding
31
New
4
Increased
15
Reduced
5
Closed
2
Top Buys
| 1 |
ALDR
Alder Biopharmaceuticals, Inc.
ALDR
|
$61.2M |
| 2 |
JUNO
Juno Therapeutics, Inc.
JUNO
|
$24M |
| 3 |
KITE
Kite Pharma, Inc.
KITE
|
$21.3M |
| 4 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$19M |
| 5 |
CEMP
Cempra, Inc.
CEMP
|
$18.7M |
Top Sells
| 1 |
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
|
$100M |
| 2 |
IMGN
Immunogen Inc
IMGN
|
$25.4M |
| 3 |
Gilead Sciences
GILD
|
$17.6M |
| 4 |
Innoviva
INVA
|
$9.04M |
| 5 |
Halozyme
HALO
|
$7.82M |
Sector Composition
| 1 | Healthcare | 82.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CELG
1
DELISTED
Celgene Corp
CELG
| $413M | 11.18% |
3,564,298
+10,000
| +0.3% | +$1.16M |
|
2
Incyte
INCY
$16.5B
| $390M | 10.57% |
3,740,406
-51,461
| -1% | -$5.36M |
|
3
Ionis Pharmaceuticals
IONS
$6.79B
| $341M | 9.25% |
5,929,426
+200,000
| +3% | +$11.5M |
|
|
4
Gilead Sciences
GILD
$140B
| $318M | 8.62% |
2,715,596
-150,000
| -5% | -$17.6M |
|
|
RDUS
5
DELISTED
Radius Health, Inc.
RDUS
| $266M | 7.2% |
3,922,140
+200,000
| +5% | +$13.5M |
|
6
Agios Pharmaceuticals
AGIO
$2.19B
| $221M | 6% |
1,989,921
+140,000
| +8% | +$15.6M |
|
7
Vertex Pharmaceuticals
VRTX
$100B
| $165M | 4.47% |
1,334,445
| – | – |
|
8
Neurocrine Biosciences
NBIX
$13.8B
| $154M | 4.17% |
3,221,552
+20,000
| +0.6% | +$955K |
|
|
MDVN
9
DELISTED
MEDIVATION, INC.
MDVN
| $147M | 4% |
1,290,556
+15,850
| +1% | +$1.81M |
|
|
ALXN
10
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $141M | 3.81% |
777,428
+105,000
| +16% | +$19M |
|
|
11
Halozyme
HALO
$8.56B
| $137M | 3.72% |
6,077,168
-346,202
| -5% | -$7.82M |
|
|
RCPT
12
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
| $126M | 3.43% |
665,272
+30,000
| +5% | +$5.7M |
|
13
Alnylam Pharmaceuticals
ALNY
$58.5B
| $116M | 3.14% |
965,499
+130,000
| +16% | +$15.6M |
|
14
Regeneron Pharmaceuticals
REGN
$61.5B
| $101M | 2.74% |
198,000
| – | – |
|
15
Novavax
NVAX
$1.21B
| $91.1M | 2.47% |
8,180,000
-270,000
| -3% | -$3.01M |
|
|
TTPH
16
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
| $71.5M | 1.94% |
1,507,114
+30,000
| +2% | +$1.42M |
|
|
ALDR
17
DELISTED
Alder Biopharmaceuticals, Inc.
ALDR
| $61.2M | 1.66% |
+1,155,150
| New | +$61.2M |
|
18
Puma Biotechnology
PBYI
$254M
| $60.9M | 1.65% |
521,991
| – | – |
|
|
CEMP
19
DELISTED
Cempra, Inc.
CEMP
| $60.7M | 1.65% |
1,766,900
+543,900
| +44% | +$18.7M |
|
20
PTC Therapeutics
PTCT
$3.92B
| $60.3M | 1.63% |
1,252,912
+75,000
| +6% | +$3.61M |
|
|
CLVS
21
DELISTED
Clovis Oncology, Inc.
CLVS
| $54.3M | 1.47% |
618,188
| – | – |
|
|
TSRO
22
DELISTED
TESARO, Inc.
TSRO
| $53.2M | 1.44% |
904,582
+50,000
| +6% | +$2.94M |
|
|
ICPT
23
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $43.6M | 1.18% |
180,719
+25,719
| +17% | +$6.21M |
|
|
INFI
24
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| $29.6M | 0.8% |
2,700,737
+80,000
| +3% | +$876K |
|
|
JUNO
25
DELISTED
Juno Therapeutics, Inc.
JUNO
| $24M | 0.65% |
+450,000
| New | +$24M |
|